Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An Open-label, Multicenter, Randomized Phase III Trial Comparing Safety and Efficacy of Personalized Versus Non-personalized Radionuclide Therapy With 177Lu (Lutetium)-DOTATOC.

NCT05387603 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT05387603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05387603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An Open-label, Multicenter, Randomized Phase III Trial Comparing Safety and Efficacy of Personalized Versus Non-personalized Radionuclide Therapy With 177Lu (Lutetium)-DOTATOC.
Lead sponsor
Lund University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
November 1, 2022
Completion date
October 1, 2026
Enrollment
300 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors